{"id":"alxn1210-iv","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Nausea"},{"rate":"7%","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting the C5 complement protein, ALXN1210 prevents the formation of the membrane attack complex (MAC), which is responsible for the destruction of cells in certain diseases.","oneSentence":"ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:53:37.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"Atypical hemolytic uremic syndrome (aHUS)"}]},"trialDetails":[{"nctId":"NCT06830798","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-02-24","conditions":"Delayed Graft Function, DGF, Kidney Transplant","enrollment":450},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT05744921","phase":"PHASE3","title":"A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-03-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":202},{"nctId":"NCT07024563","phase":"PHASE3","title":"Study of Ravulizumab in Pediatric Participants With Primary IgAN","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-06-14","conditions":"IgAN, IgAVN, Immunoglobulin A Nephropathy","enrollment":24},{"nctId":"NCT05133531","phase":"PHASE3","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":190},{"nctId":"NCT05644561","phase":"PHASE3","title":"Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-06-24","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT07308574","phase":"PHASE4","title":"Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-12-19","conditions":"aHUS, Atypical Hemolytic Uremic Syndrome","enrollment":20},{"nctId":"NCT04564339","phase":"PHASE2","title":"Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-01-19","conditions":"Lupus Nephritis, Immunoglobulin A Nephropathy","enrollment":123},{"nctId":"NCT06578949","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-10-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":18},{"nctId":"NCT05346354","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-06-23","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":12},{"nctId":"NCT04201262","phase":"PHASE3","title":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-12-09","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","enrollment":58},{"nctId":"NCT05972967","phase":"PHASE2","title":"Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab","status":"COMPLETED","sponsor":"Omeros Corporation","startDate":"2023-03-27","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12},{"nctId":"NCT03056040","phase":"PHASE3","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-05-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":202},{"nctId":"NCT03748823","phase":"PHASE3","title":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-02-19","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":139},{"nctId":"NCT03920293","phase":"PHASE3","title":"Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-03-12","conditions":"Generalized Myasthenia Gravis","enrollment":175},{"nctId":"NCT02946463","phase":"PHASE3","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-12-12","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":272},{"nctId":"NCT05396742","phase":"PHASE1","title":"Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-08-09","conditions":"Healthy","enrollment":49},{"nctId":"NCT05288660","phase":"PHASE1","title":"A Study of a Single Dose of ALXN1210 in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-08-27","conditions":"Healthy","enrollment":14},{"nctId":"NCT05288673","phase":"PHASE1","title":"A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-07-28","conditions":"Healthy","enrollment":16},{"nctId":"NCT05288829","phase":"PHASE1","title":"A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-08-19","conditions":"Healthy","enrollment":42},{"nctId":"NCT03406507","phase":"PHASE3","title":"A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-02-22","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":13},{"nctId":"NCT02605993","phase":"PHASE2","title":"Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-01-04","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":26},{"nctId":"NCT04369469","phase":"PHASE3","title":"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-05-10","conditions":"COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome","enrollment":202},{"nctId":"NCT02598583","phase":"PHASE1, PHASE2","title":"Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-11-12","conditions":"PNH","enrollment":13},{"nctId":"NCT04390464","phase":"PHASE4","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-05-08","conditions":"COVID19","enrollment":1167}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ravulizumab","Ultomiris"],"phase":"phase_1","status":"active","brandName":"ALXN1210 IV","genericName":"ALXN1210 IV","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}